CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：CAR-T Therapy Beyond B-Cell Hematological Malignancies.
CAR-T Therapy Beyond B-Cell Hematological Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管 CAR-T 细胞在某些血液系统恶性肿瘤中取得了进展，主要来自 B 细胞来源的肿瘤，如非霍奇金淋巴瘤、急性淋巴细胞白血病和多发性骨髓瘤，但正如临床研究结果所证明的那样，其他血液系统和非血液系统疾病中也有相当一部分可从这种创新治疗中获益。CAR-T 在急性 T 淋巴细胞白血病、急性髓系白血病、实体瘤、自身免疫性疾病和感染中的应用遇到了不同于血液系统 B 细胞疾病的局限性。为了克服这些限制，基于不同分子工程平台的策略已被设计出来，并将在下文进行阐述。本文旨在概述 CAR-T 在目前所治疗疾病之外的病理中的应用，重点介绍这些应用场景中的局限性和所取得的结果。
Despite the advances of CAR-T cells in certain hematological malignancies, mostly from B-cell derivations such as non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, a significant portion of other hematological and non-hematological pathologies can benefit from this innovative treatment, as the results of clinical studies are demonstrating.
The clinical application of CAR-T in the setting of acute T-lymphoid leukemia, acute myeloid leukemia, solid tumors, autoimmune diseases and infections has encountered limitations that are different from those of hematological B-cell diseases.
To overcome these restrictions, strategies based on different molecular engineering platforms have been devised and will be illustrated below. The aim of this manuscript is to provide an overview of the CAR-T application in pathologies other than those currently treated, highlighting both the limits and results obtained with these settings.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
